Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Phylogica — Investor Presentation (July 2019)
16 slides from Pyc Therapeutics's investor presentation, Jul 24, 2019
Slide 1: Building a pipeline of drugs for blinding eye diseases
For personal use only PYC flagship program – building a pipeline of drugs for the treatment of blinding eye diseases July 2019
Slide 2: Disclaimer
Disclaimer For personal use only The purpose of this presentation is to provide an update of the business of Phylogica Limited (ASX:PYC) [‘Phylogica’]. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Ac
Slide 3: Executive Summary
Executive Summary For personal use only We are a drug development company on the path to the clinic 1. Background Overview of our technology – taking ‘big things’ inside cells An introduction to Anti Sense Oligonucleotides (the ‘next big thing’) Why do we do this? Inherited Retinal Dystrophies
Slide 4: Background
For personal use only Background The delivery platform, the drug and the disease 4
Slide 5: Our technology addresses a major unmet need: the delivery challenge
Our technology addresses a major unmet need in drug development – ‘the delivery challenge’ For personal use only Large drugs are not able to get inside cells to reach the highest value drug targets on their own “The great thing about this [drug] technology is that it's precise and safe… But it does
Slide 6: Combining our platform with Anti Sense Oligos
We have chosen to combine the power of our platform with the potency and precision of a new class of drugs (Anti Sense Oligos) For personal use only Anti Sense Oligonucleotides (ASOs) act on the RNA inside cells The CPP delivers the ASO into the nucleus of the cell… And the ASO binds to the mRNA to
Slide 7: Using this new drug class to treat diseases of the eye
We are using this new class of drugs to treat diseases of the eye – a large global opportunity For personal use only Treatment of vision loss is a Inherited Retinal Diseases (IRD) Our ability to treat vision loss is significant global burden are a leading cause of blindness rapidly improving Vision
Slide 8: The problem: Drug delivery to the retina
For personal use only The problem Drug delivery to the retina 8
Slide 9: Drug delivery in the eye is a complex challenge
Drug delivery in the eye is a complex challenge For personal use only “Delivery of drugs to the posterior eye is challenging, owing to anatomical and physiological constrains of the eye1” “Drug delivery to the posterior segment of the eye is an area of intense investigation and immense potential2” 1
Slide 10: Our progress
For personal use only Our progress We are ramping up towards clinical development 10
Slide 11: We have proven we can get to the target cell layer
We have proven that we can get to the target cell layer For personal use only A fluorescently ‘labelled’ CPP localises to our target cellular layer of interest within 1 hour of administration CPP + fluorescent tag 11
Slide 12: We have proven we can get into the target cell layer
We have proven that we can get into the target cell layer Our CPP enables the ASO to achieve its effect We can leverage these result to treat any For personal use only in the nucleus of cells retinal disease of interest Exon skipping by SMN1 ASO day 5 following a single intravitreal injection in a r
Slide 13: We have a major competitive advantage
We have a major competitive advantage… For personal use only Competitive evaluation Implications Head to head evaluation of ability of PYC’s CPP to deliver ASO cargo to target cellular layer (PYC CPP versus benchmark RXR4 CPP) PYC’s CPP achieves >400% more activity in the target cellular layer T
Slide 14: Using it to create a differentiated product
And we are using it to create a differentiated product For personal use only Objective We are developing multiple drugs for the treatment of blinding eye Critical read-outs diseases and are taking them through clinical development Projected timeline Q2 2019 Q3 2019 Q4 2019 Q1 2020 Efficacy in animal
Slide 15: Our path to market is well established
Our path to market is well established and comes with significant advantages For personal use only Successful navigation of pre-clinical development leaves us in a strong position in the clinic Developmental stage IND-enabling Phase 1 Phase 2 Phase 3 Marketing Advantages Multiple leads Small stu
Slide 16: Successful execution of our strategy will build shareholder value
Successful execution of our strategy will build substantial shareholder value For personal use only Summary We are a drug development company on the path to the clinic • We have a powerful platform technology in the form of our CPPs • We have combined it with a cargo class that is set to have a majo